Login to Your Account

OSI, Genentech, Roche File First Portions Of Tarceva Rolling NDA

By Kim Coghill

Thursday, January 22, 2004
OSI Pharmaceuticals Inc. and partners Genentech Inc. and Roche Holdings Inc. filed the first sections of a rolling new drug application for the cancer candidate Tarceva, an endothelial growth factor receptor inhibitor. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription